Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.490
-0.060 (-3.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Sunshine Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 9.69 | 16.29 | 21.83 | 2.05 | 0.99 | Upgrade
|
| Short-Term Investments | - | - | - | 0.01 | 0.01 | Upgrade
|
| Cash & Short-Term Investments | 9.69 | 16.29 | 21.83 | 2.05 | 1 | Upgrade
|
| Cash Growth | -40.55% | -25.36% | 963.27% | 105.79% | 1974.15% | Upgrade
|
| Accounts Receivable | 3.87 | 2.55 | 1.91 | 0.01 | 0 | Upgrade
|
| Receivables | 3.87 | 2.55 | 1.91 | 0.01 | 0 | Upgrade
|
| Inventory | 11.28 | 5.73 | 3.29 | 0.11 | 0.02 | Upgrade
|
| Prepaid Expenses | 1.13 | 0.31 | 0.28 | 0.03 | 0 | Upgrade
|
| Total Current Assets | 25.97 | 24.89 | 27.31 | 2.2 | 1.03 | Upgrade
|
| Property, Plant & Equipment | 1.48 | 1.01 | 1.15 | 0.01 | 0.02 | Upgrade
|
| Other Intangible Assets | 3.02 | 1.44 | 0.78 | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | 0.09 | - | - | - | - | Upgrade
|
| Total Assets | 30.56 | 27.35 | 29.24 | 2.2 | 1.05 | Upgrade
|
| Accounts Payable | 5.54 | 2.59 | 2.8 | 0.04 | 0.06 | Upgrade
|
| Accrued Expenses | - | - | - | 0.05 | 0.02 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.14 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 0.82 | Upgrade
|
| Current Portion of Leases | 0.21 | 0.12 | 0.12 | - | - | Upgrade
|
| Current Income Taxes Payable | 0.27 | 0.3 | 0.37 | - | - | Upgrade
|
| Other Current Liabilities | 0.3 | 2.55 | 3.63 | - | - | Upgrade
|
| Total Current Liabilities | 6.31 | 5.55 | 6.93 | 0.09 | 1.05 | Upgrade
|
| Long-Term Debt | - | - | - | 1.9 | 0.95 | Upgrade
|
| Long-Term Leases | 0.74 | 0.54 | 0.64 | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 0.05 | 0.04 | - | - | Upgrade
|
| Total Liabilities | 7.06 | 6.14 | 7.62 | 1.99 | 2 | Upgrade
|
| Common Stock | 0 | 0 | 0.02 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 93.35 | 84.42 | 80.84 | 32.79 | 19.17 | Upgrade
|
| Retained Earnings | -69.04 | -63.91 | -59.4 | -32.66 | -20.22 | Upgrade
|
| Comprehensive Income & Other | -0.83 | 0.7 | 0.16 | -0.02 | -0 | Upgrade
|
| Total Common Equity | 23.49 | 21.21 | 21.63 | 0.11 | -1.05 | Upgrade
|
| Shareholders' Equity | 23.5 | 21.21 | 21.63 | 0.21 | -0.95 | Upgrade
|
| Total Liabilities & Equity | 30.56 | 27.35 | 29.24 | 2.2 | 1.05 | Upgrade
|
| Total Debt | 0.95 | 0.66 | 0.77 | 1.9 | 1.91 | Upgrade
|
| Net Cash (Debt) | 8.73 | 15.63 | 21.06 | 0.15 | -0.92 | Upgrade
|
| Net Cash Growth | -44.14% | -25.77% | 13687.37% | - | - | Upgrade
|
| Net Cash Per Share | 12.45 | 1219.08 | - | - | - | Upgrade
|
| Filing Date Shares Outstanding | 2.71 | 0.05 | 0.01 | - | - | Upgrade
|
| Total Common Shares Outstanding | 2.58 | 0.01 | 0.01 | - | - | Upgrade
|
| Working Capital | 19.65 | 19.34 | 20.38 | 2.1 | -0.03 | Upgrade
|
| Book Value Per Share | 9.10 | 1513.44 | 1915.04 | - | - | Upgrade
|
| Tangible Book Value | 20.47 | 19.76 | 20.85 | 0.11 | -1.05 | Upgrade
|
| Tangible Book Value Per Share | 7.93 | 1410.37 | 1846.25 | - | - | Upgrade
|
| Machinery | 0.79 | 0.54 | 0.48 | - | 0.07 | Upgrade
|
| Leasehold Improvements | 0.09 | 0.02 | - | - | - | Upgrade
|
Updated Nov 5, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.